DRDO’s anti-Covid drug 2DG is expected to be available by mid-June

Hyderabad: Emergency use approval has been granted in India for Anti-Covid-9 therapeutic application of the drug 2-deoxy-D-Glucose (2DG) developed by INMAS, a lab of the DRDO in collaboration with Dr Reddy's Laboratories.

2DG is an oral anti-viral drug that can be administered only upon prescription to hospitalized moderate to severe Covid-19 patients as adjunct (add on) therapy along with existing standard of care, Hyderabad-based pharmaceutical giant Dr Reddy's lab said in a release here on Wednesday.

Commercial launch and supply of 2DG to major government and private hospitals is expected to commence in mid-June and the Price per sachet is being determined with a view to making it accessible and affordable to as many patients as possible and will be announced soon, it said.

The Pharma company also cautioned to beware of agents selling spurious or illegal products in the name of 2DG and also beware of unverified messages relating to 2DG circulating on social media and on WhatsApp. (UNI)